Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone415-231-5660
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.51 million
Profitability
Miscellaneous
Employees91
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable
Alector (NASDAQ:ALEC) Frequently Asked Questions
What is Alector's stock symbol?
Alector trades on the NASDAQ under the ticker symbol "ALEC."
How were Alector's earnings last quarter?
Alector Inc (NASDAQ:ALEC) issued its quarterly earnings results on Monday, August, 12th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.03. The company had revenue of $6.92 million for the quarter. View Alector's Earnings History.
When is Alector's next earnings date?
What price target have analysts set for ALEC?
6 analysts have issued twelve-month price targets for Alector's stock. Their forecasts range from $26.00 to $27.00. On average, they expect Alector's share price to reach $26.6667 in the next twelve months. This suggests a possible upside of 34.0% from the stock's current price. View Analyst Price Targets for Alector.
What is the consensus analysts' recommendation for Alector?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alector.
Has Alector been receiving favorable news coverage?
News coverage about ALEC stock has been trending negative on Friday, InfoTrie reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alector earned a coverage optimism score of -2.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Alector.
Who are some of Alector's key competitors?
Some companies that are related to Alector include Adaptive Biotechnologies (ADPT), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Allogene Therapeutics (ALLO), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Regenxbio (RGNX), Coherus Biosciences (CHRS) and Audentes Therapeutics (BOLD).
What other stocks do shareholders of Alector own?
Who are Alector's key executives?
Alector's management team includes the folowing people:
- Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
- Dr. Arnon Rosenthal, Co-Founder, CEO, Pres & Director (Age 64)
- Dr. Robert Paul M.D., Ph.D., Chief Medical Officer (Age 51)
- Dr. Robert S. King, Chief Devel. Officer (Age 56)
- Dr. Asa Abeliovich M.D., Ph.D., Co-Founder
When did Alector IPO?
(ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays acted as the underwriters for the IPO.
When did Alector's lock-up period expire?
Alector's lock-up period expired on Tuesday, August 6th. Alector had issued 9,250,000 shares in its initial public offering on February 7th. The total size of the offering was $175,750,000 based on an initial share price of $19.00. Since the expiration of Alector's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who are Alector's major shareholders?
Alector's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.32%), BlackRock Inc. (1.26%), Highline Capital Management L.P. (0.94%), JPMorgan Chase & Co. (0.43%), Bamco Inc. NY (0.35%) and Artal Group S.A. (0.33%). Company insiders that own Alector stock include Orbimed Advisors Llc and Robert Paul. View Institutional Ownership Trends for Alector.
Which institutional investors are selling Alector stock?
ALEC stock was sold by a variety of institutional investors in the last quarter, including Highline Capital Management L.P., Artal Group S.A. and Platinum Investment Management Ltd.. Company insiders that have sold Alector company stock in the last year include Orbimed Advisors Llc and Robert Paul. View Insider Buying and Selling for Alector.
Which institutional investors are buying Alector stock?
ALEC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Bamco Inc. NY, JPMorgan Chase & Co., Cannell Peter B & Co. Inc., Oppenheimer & Co. Inc., Vanguard Group Inc., Citadel Advisors LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Alector.
How do I buy shares of Alector?
Shares of ALEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Alector's stock price today?
One share of ALEC stock can currently be purchased for approximately $19.90.
How big of a company is Alector?
Alector has a market capitalization of $1.37 billion and generates $27.51 million in revenue each year. The company earns $-52,250,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Alector employs 91 workers across the globe.View Additional Information About Alector.
What is Alector's official website?
How can I contact Alector?
Alector's mailing address is 151 OYSTER POINT BLVD. SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-231-5660 or via email at [email protected]
MarketBeat Community Rating for Alector (NASDAQ ALEC)
MarketBeat's community ratings are surveys of what our community members think about Alector and other stocks. Vote "Outperform" if you believe ALEC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALEC will underperform the S&P 500 over the long term. You may vote once every thirty days.
